Equities

Polarean Imaging PLC

Polarean Imaging PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)1.25
  • Today's Change-0.10 / -7.41%
  • Shares traded6.29m
  • 1 Year change-93.76%
  • Beta0.4447
Data delayed at least 20 minutes, as of May 24 2024 16:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Polarean Imaging PLC is a medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI). The Company and its subsidiary company operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. The Company’s technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. It operates in Canada, Germany, United Kingdom and United States. The Company’s subsidiary is Polarean, Inc.

  • Revenue in GBP (TTM)267.90k
  • Net income in GBP-11.25m
  • Incorporated2016
  • Employees28.00
  • Location
    Polarean Imaging PLC2500 Meridian Pkwy #175DURHAM 27713United StatesUSA
  • Phone+1 (919) 206-7900
  • Fax+1 (919) 206-7901
  • Websitehttps://polarean.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Luxxu Group Ltd3.43m-4.28m3.52m56.00--0.3954--1.03-0.0791-0.07910.06330.16440.23560.59830.8658609,813.30-29.42-33.26-33.95-35.127.795.23-124.85-126.114.40-4.040.2545---50.83-21.6118.06------
HitiQ Ltd492.71k-2.59m3.66m----33.93--7.43-0.0197-0.01970.00390.00060.2127--5.71---111.86---256.43-------525.82-----63.710.0991--26.43--27.49------
Insplorion AB209.00k-1.67m3.78m12.00--1.98--18.09-2.52-2.520.18711.090.0797-2.105.58218,538.50-63.67-29.27-74.89-34.48238.58260.36-799.37-791.031.63--0.0409---2.70-4.88-14.18--12.48--
Reflect Scientific Inc994.97k-269.32k3.83m7.00--2.62--3.85-0.004-0.0040.01480.02170.51290.61845.72181,111.40-13.8811.10-16.4313.2156.0662.48-27.0710.002.21--0.00---47.09-6.99-613.46------
Thermogenesis Holdings Inc7.54m-11.57m3.86m25.00--5.05--0.5123-4.99-4.993.140.12260.64423.259.13384,400.00-105.49-78.08-221.76-133.9421.1029.01-163.77-133.660.3739-0.80281.35---9.90-0.4739-59.49--6.96--
Mantex AB502.44k-1.18m4.27m----2.67--8.50-0.0788-0.07880.03320.08670.23980.248842.92---56.37-64.71-64.06-76.8279.0563.54-235.05-300.724.43-69.720.1601--373.264.57-3.37------
Dorsavi Ltd764.52k-805.67k4.35m34.00--5.96--5.68-0.0029-0.00290.00270.00240.62470.42281.87---65.84-60.69-97.79-88.7184.5888.19-105.38-165.451.83-62.210.1012---25.62-14.77-18.52---52.15--
Telesis Bio Inc19.33m-36.99m4.53m137.00------0.2342-28.31-28.3114.8012.940.32313.275.58179,802.90-59.34---67.10--60.43---183.66--3.08-35.890.2015--0.2697---1.14------
Hanvey Group Holdings Ltd18.65m-1.99m4.81m110.00--2.56--0.2577-0.1196-0.11961.120.11320.82845.049.311,687,882.00-8.89-6.91-23.71-19.1423.3324.18-10.74-7.460.9283-1.070.8947---31.880.3471-85.65---39.81--
Polarean Imaging PLC267.90k-11.25m5.19m28.00--0.274--19.36-0.0528-0.05280.00130.04550.01530.11340.19719,567.74-64.22-59.80-72.25-68.3839.6559.23-4,201.18-574.074.66--0.0225---12.86-3.540.7877--30.60--
Biolidics Ltd158.13k-1.69m5.20m15.00------32.86-0.0045-0.00450.0004-0.00230.0991.191.1118,133.33-105.67-51.21---69.1957.7241.13-1,068.02-165.860.239-31.02-----47.170.73273.46------
Aurora Solar Technologies Inc6.14m-990.82k5.71m----1.69--0.9313-0.0098-0.00980.05050.02660.91081.517.98---14.71-82.57-22.77-106.4452.4143.93-16.15-135.081.22-39.660.0665----17.05-5.49--13.30--
Memphasys Ltd24.50k-2.35m6.40m24.00--1.54--261.35-0.0046-0.00460.000050.00590.00330.2732-----31.43-16.26-46.11-19.7344.48---9,600.13-21,518.040.1368-11.780.456---43.39---63.43--8.14--
Precipio Inc12.41m-3.85m6.77m51.00--0.6574--0.5456-3.73-3.7311.608.930.877317.8517.93310,039.20-27.20-44.98-34.82-58.6839.1428.80-31.00-118.070.6201-350.950.0278--61.4639.6252.04--5.37--
Data as of May 24 2024. Currency figures normalised to Polarean Imaging PLC's reporting currency: UK Pound GBX

Institutional shareholders

13.69%Per cent of shares held by top holders
HolderShares% Held
Yarra Investment Management Ltd.as of 28 Feb 20239.09m4.20%
Chelverton Asset Management Ltd.as of 28 Feb 20238.50m3.93%
Canaccord Genuity Wealth Ltd.as of 28 Feb 20237.11m3.29%
Unicorn Asset Management Ltd.as of 30 Apr 20243.18m1.47%
Aviva Investors Global Services Ltd.as of 29 Feb 20241.02m0.47%
Premier Fund Managers Ltd.as of 30 Nov 2023434.76k0.20%
Thornbridge Investment Management LLPas of 31 Oct 2022275.35k0.13%
More ▼
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.